Telix has selected IBA to supply four cyclotrons for its radiopharmacies in the United States as part of the expansion of its industrial footprint. The collaboration highlights the complementarity of Wallonia’s ecosystem, combining IBA’s technological expertise with Telix’s industrial network to support more accessible nuclear medicine.
The Australian company, which operates a production site in Wallonia for the manufacturing of radioisotopes as well as commercial and clinical products for the Europe–Middle East–Africa (EMEA) region, has chosen the Walloon company IBA (Ion Beam Applications) to supply four Cyclone® KIUBE cyclotrons. These will be installed at selected RLS Radiopharmacies (RLS) sites in the United States.
This investment supports the strategic expansion of Telix’s industrial footprint in the United States, with the objective of strengthening supply chain resilience and enabling the in-house production of essential therapeutic and diagnostic isotopes, as well as radiopharmaceuticals for oncology care.
When establishing operations in Belgium in 2018, Telix chose Wallonia for its ecosystem and the presence of all key players in the radiopharmacy field within close proximity. It is therefore no surprise to see Telix and IBA collaborating today.
By combining IBA’s expertise in cyclotrons with Telix’s production and distribution network, this partnership strengthens the collective capacity to meet the growing demand for advanced PET imaging tracers and other integrated theranostic solutions.
Telix selected the Cyclone® KIUBE 180 model for its industrial performance and scalability. Each installation will be equipped with the QUANTM® Irradiation System (QIS®) developed by ARTMS, a Telix subsidiary.
Isabelle Anneet (AWEX)
